Recombinant human granulocyte-macrophage colony - stimulating factor therapy and endogenous plasma GM - CSF, IL - 3, IL - 4 concentrations in pediatric patients with solid tumors

Basit Öğe Kaydı
dc.contributor.authorÇetingül N.
dc.contributor.authorKütükçüler N.
dc.contributor.authorKantar M.
dc.contributor.authorKavakli K.
dc.contributor.authorNişli G.
dc.contributor.authorÇaglayan S.
dc.contributor.authorÖztop S.
dc.date.accessioned2019-10-27T00:32:12Z
dc.date.available2019-10-27T00:32:12Z
dc.date.issued1997
dc.departmentEge Üniversitesien_US
dc.description.abstractTen pediatric patients with solid tumors and chemotherapy-induced neutropenia were given recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM CSF). The duration of the neutropenic phase was then compared with the results obtained from eight patients also with solid tumors, but not treated with rHuGM-CSF. It was found that rHuGM-CSF treatment significantly decreased the duration of the neutropenic phase. Endogenous plasma GM-CSF, IL-3, and IL-4 levels were also measured in the study group and in healthy children. No significant correlation has been found between plasma GM-CSF concentrations and absolute neutrophil counts. However, IL-3 levels of the neutropenic patients positively correlated with platelet counts. Furthermore, IL-4 concentrations were positively correlated with the GM-CSF level in the same individual. Plasma GM-CSF, IL-3, and IL-4 levels in the neutropenic solid tumor group were found to be significantly higher than those in healthy children. Plasma IL-4 levels were significantly elevated In patients with osteosarcoma as compared to patients with other solid tumors. Although rHuGM-CSF has a half-life of only two to three hours, one day after rHuGM-CSF therapy, plasma GM-CSF levels were found to be higher than initial values. In contrast, plasma IL-4 values decreased significantly after administration of rHuGM-CSF. The probable mechanisms for the changes In cytokine levels are discussed.en_US
dc.identifier.endpage481en_US
dc.identifier.issn0041-4301
dc.identifier.issue4en_US
dc.identifier.pmid9433149en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage473en_US
dc.identifier.urihttps://hdl.handle.net/11454/23707
dc.identifier.volume39en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIL-3en_US
dc.subjectIL-4en_US
dc.subjectNeutropeniaen_US
dc.subjectPlasma GM-CSF concentrationen_US
dc.subjectrHuGM-CSFen_US
dc.subjectSolid tumoren_US
dc.titleRecombinant human granulocyte-macrophage colony - stimulating factor therapy and endogenous plasma GM - CSF, IL - 3, IL - 4 concentrations in pediatric patients with solid tumorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu